QT interval and drug therapy: Recommendations for drug prescription in patients with the long QT syndrome.

被引:0
|
作者
Le Heuzey, JY
Davy, JM
Weissenburger, J
Guicheney, P
Le Marec, H
Chevalier, P
Denjoy, I
Leenhardt, A
Charpentier, F
Coumel, P
机构
[1] Hop Broussais, Serv Cardiol A, F-75014 Paris, France
[2] Hop Arnaud de Villeneuve, Serv Cardiol, F-34000 Montpellier, France
[3] Hop St Antoine, Pharmacol Lab, F-75012 Paris, France
[4] Hop La Pitie Salpetriere, INSERM U153, F-75013 Paris, France
[5] Hop Laennec, Serv Cardiol, F-44035 Nantes, France
[6] Hop Louis Pradel, Serv Cardiol, F-69394 Lyon 03, France
[7] Hop Lariboisiere, Serv Cardiol, F-75010 Paris, France
[8] Hop Laennec, INSERM CJF 9601, F-44035 Nantes, France
来源
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The genetics of the long QT syndrome are now better understood. However, there is much heterogeneity as three different genes have already been identified affecting the function of sodium and potassium channels. The aim of these recommendations is to draw up a list of drugs which are contraindicated or not recommended in patients with congenital long QT syndromes. The conraindicated drugs are those with which torsades de pointe have already been described. Drugs not recommended are substances which are not electrohysiologically neutral and for which, in View of their modes of action, their metabolism or belonging to a particular therapeutic class, make them very difficult to use in those patients. It is therefore better not to prescribe them whenever possible in this condition. These substances belong mainly to cardiovascular (especially antiarrhythmic), psychotropic, anti-infectious and antiallergic groups of drugs.
引用
收藏
页码:59 / 66
页数:8
相关论文
共 50 条
  • [1] Diagnostic performance of dynamics of QT interval in long QT syndrome.
    Neyroud, N
    Denjoy, I
    Blanche, PM
    Chevret, S
    Guicheney, P
    Badilini, F
    Lucet, V
    Leenhardt, A
    Coumel, P
    CIRCULATION, 1996, 94 (08) : 1179 - 1179
  • [2] Recurrent syncope - Drug induced long QT syndrome.
    Mansfield, RJR
    Thomas, RD
    POSTGRADUATE MEDICAL JOURNAL, 2001, 77 (907) : 344 - +
  • [3] Long QT syndrome.
    Lupoglazoff, JM
    Denjoy, I
    Guicheney, P
    Casasoprana, A
    Coumel, P
    ARCHIVES DE PEDIATRIE, 2001, 8 (05): : 525 - 534
  • [4] Drug therapy: Drug-induced prolongation of the QT interval
    Roden, DM
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10): : 1013 - 1022
  • [5] Dynamics of QT interval in a patient with long QT syndrome and a normal QT interval
    Nakagawa, M
    Iwao, T
    Ishida, S
    Takahashi, N
    Yonemochi, H
    Asada, M
    Shimada, S
    Saikawa, T
    Ito, M
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1998, 62 (03): : 215 - 218
  • [6] Drug-induced long QT syndrome. Relevancy in intensive care medicine
    Laszlo, R.
    Laszlo, S.
    Kettering, K.
    Schreieck, J.
    Riessen, R.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2012, 107 (03) : 197 - +
  • [7] The long-QT syndrome.
    Allan, WC
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (07): : 514 - 515
  • [8] Inherited long QT syndrome revealed by drug to drug interaction
    Eiden, C.
    Peyriere, H.
    Tichit, R.
    Cociglio, M.
    Amedro, P.
    Blayac, J. P.
    Margueritte, G.
    Hillaire-Buys, D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 64 - 64
  • [9] Drug-Induced Long QT Syndrome
    Kannankeril, Prince
    Roden, Dan M.
    Darbar, Dawood
    PHARMACOLOGICAL REVIEWS, 2010, 62 (04) : 760 - 781
  • [10] Drug-induced long QT syndrome and drug development
    Ritter, J. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (03) : 341 - 344